高增殖性脑膜瘤包含具有不同生物学和临床特征的DNA甲基化亚组
研究重新分析565例脑膜瘤DNA甲基化谱,将高增殖性组分为增殖性和高代谢性两个亚组,二者FOXM1靶基因富集不同,且DNA甲基化亚组较组别能更好预测术后结局。
要点
- 高增殖性脑膜瘤可分为增殖性与高代谢性两个DNA甲基化亚组。
- 无FOXM1靶基因富集的高增殖性亚组由大分子代谢基因程序区分。
- DNA甲基化亚组较DNA甲基化组别进一步改善术后结局预测。
核心结论
- 脑膜瘤可分为三个DNA甲基化组,高增殖性脑膜瘤可再分为增殖性和高代谢性亚组,各具不同生物学和临床特征。
研究设计与样本
- 重新分析来自独立发现机构(n=200)或验证机构(n=365)且有全面临床随访的565例脑膜瘤DNA甲基化谱,并分类为Merlin完整、免疫富集或高增殖性DNA甲基化组。
- 分析发现队列(n=200)或验证队列(n=302)的RNA测序数据以识别亚组。
主要发现
- RNA测序揭示高增殖性脑膜瘤两个亚组间FOXM1靶基因富集存在差异。
- 差异表达和本体分析显示,无FOXM1靶基因富集的高增殖性脑膜瘤亚组由驱动大分子代谢的基因表达程序区分。
- 遗传、表观遗传、基因表达或细胞特征分析显示,高增殖性脑膜瘤亚组与增殖性或高代谢性脑膜瘤一致,后者此前使用整合分子模型与Merlin完整和免疫富集肿瘤一同报道。
- 将DNA甲基化亚组加入临床模型较加入DNA甲基化组别进一步改善了术后结局预测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas, the most common primary intracranial tumors, can be separated into 3 DNA methylation groups with distinct biological drivers, clinical outcomes, and therapeutic vulnerabilities. Alternative meningioma grouping schemes using copy number variants, gene expression profiles, somatic short variants, or integrated molecular models have been proposed. These data suggest meningioma DNA methylation groups may harbor subgroups unifying contrasting theories of meningioma biology. METHODS: A total of 565 meningioma DNA methylation profiles from patients with comprehensive clinical follow-up at independent discovery (n = 200) or validation (n = 365) institutions were reanalyzed and classified into Merlin-intact, Immune-enriched, or Hypermitotic DNA methylation groups. RNA sequencing from the discovery (n = 200) or validation (n = 302) cohort were analyzed in the context of DNA methylation groups to identify subgroups. Biological features and clinical outcomes were analyzed across meningioma grouping schemes. RESULTS: RNA sequencing revealed differential enrichment of FOXM1 target genes across two subgroups of Hypermitotic meningiomas. Differential expression and ontology analyses showed the subgroup of Hypermitotic meningiomas without FOXM1 target gene enrichment was distinguished by gene expression programs driving macromolecular metabolism. Analysis of genetic, epigenetic, gene expression, or cellular features revealed Hypermitotic meningioma subgroups were concordant with Proliferative or Hypermetabolic meningiomas, which were previously reported alongside Merlin-intact and Immune-enriched tumors using an integrated molecular model. The addition of DNA methylation subgroups to clinical models refined the prediction of postoperative outcomes compared to the addition of DNA methylation groups. CONCLUSIONS: Meningiomas can be separated into three DNA methylation groups and Hypermitotic meningiomas can be subdivided into Proliferative and Hypermetabolic subgroups, each with distinct biological and clinical features.
引用
- Choudhury A, Chen WC, Lucas CG, et al. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023. PMID: 36227281. doi:10.1093/neuonc/noac224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。